Pharmocann Global Valuation

Is PMCN-M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PMCN-M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PMCN-M's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PMCN-M's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PMCN-M?

Key metric: As PMCN-M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PMCN-M. This is calculated by dividing PMCN-M's market cap by their current revenue.
What is PMCN-M's PS Ratio?
PS Ratio	0.3x
Sales	₪13.45m
Market Cap	₪3.73m

PMCN-M key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-0.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PMCN-M's PS Ratio compare to its peers?

The above table shows the PS ratio for PMCN-M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.1x
YBRD Y.B Urban Renewal - Residential Development	54.7x	n/a	₪29.4m
TKUN Tikun Olam-Cannbit Pharmaceuticals	0.7x	n/a	₪29.2m
REKA Rekah Pharmaceutical Industry	0.5x	n/a	₪162.3m
SEMG Seach Medical Group	0.6x	n/a	₪98.0m
PMCN-M Pharmocann Global	0.3x	n/a	₪3.7m

Price-To-Sales vs Peers: PMCN-M is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (14.1x).

Price to Sales Ratio vs Industry

How does PMCN-M's PS Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

49 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.7x	10.3%
PMCN-M Pharmocann Global	0.3x	n/a	US$1.02m

49 Companies		Estimated Growth	Market Cap
Industry Avg.	2.7x	16.7%
PMCN-M Pharmocann Global	0.3x	n/a	US$1.02m

No more companies

Price-To-Sales vs Industry: PMCN-M is good value based on its Price-To-Sales Ratio (0.3x) compared to the Asian Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is PMCN-M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PMCN-M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PMCN-M's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Evogene

₪31.7m

Operates as a computational biology company.

EVGN

₪5.92

-8.7%

-73.1%

Protalix BioTherapeutics

US$112.5m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

PLX

US$7.33

-0.1%

97.5%